SOX2 expression is regulated by BRAF and contributes to poor patient prognosis in colorectal cancer

PLoS ONE

Volumn 9, Issue 7, 2014, Pages

  Lundberg, Ida V ^a   Burström, Anna Löfgren ^a   Edin, Sofia ^a   Eklöf, Vincy ^a   Öberg, Åke ^a   Stenling, Roger ^a   Palmqvist, Richard ^a   Wikberg, Maria L ^a  

^a UMEÅ UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; FIBROBLAST GROWTH FACTOR RECEPTOR 1; GENOMIC DNA; K RAS PROTEIN; TRANSCRIPTION FACTOR SOX2; TRANSCRIPTION FACTOR SOX;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER TISSUE; CELL INVASION; CELL MIGRATION; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; SURVIVAL RATE; CANCER GRADING; CANCER STAGING; COLORECTAL NEOPLASMS; GENE EXPRESSION REGULATION; GENETICS; LIVER TUMOR; METABOLISM; MIDDLE AGED; MUTATION; PATHOLOGY; PROGNOSIS; SECONDARY; SURVIVAL; TUMOR CELL LINE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM GRADING; NEOPLASM STAGING; PROGNOSIS; PROTO-ONCOGENE PROTEINS B-RAF; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1; SOXB1 TRANSCRIPTION FACTORS; SURVIVAL ANALYSIS;

EID: 84904266305     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0101957     Document Type: Article

References (40)

1. Fearon ER, Vogelstein B (1990) A genetic model for colorectal tumorigenesis. Cell 61: 759-767.
2. Sarkar A, Hochedlinger K (2013) The sox family of transcription factors: versatile regulators of stem and progenitor cell fate. Cell Stem Cell 12: 15-30.
3. Avilion AA, Nicolis SK, Pevny LH, Perez L, Vivian N, et al. (2003) Multipotent cell lineages in early mouse development depend on SOX2 function. Genes Dev 17: 126-140. (Pubitemid 36062514)
4. Takahashi K, Yamanaka S (2006) Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126: 663-676. (Pubitemid 44233629)
5. Basu-Roy U, Seo E, Ramanathapuram L, Rapp TB, Perry JA, et al. (2012) Sox2 maintains self renewal of tumor-initiating cells in osteosarcomas. Oncogene 31: 2270-2282.
6. Han X, Fang X, Lou X, Hua D, Ding W, et al. (2012) Silencing SOX2 induced mesenchymal-epithelial transition and its expression predicts liver and lymph node metastasis of CRC patients. PLoS One 7: e41335.
7. Fang X, Yu W, Li L, Shao J, Zhao N, et al. (2010) ChIP-seq and functional analysis of the SOX2 gene in colorectal cancers. OMICS 14: 369-384.
8. Park ET, Gum JR, Kakar S, Kwon SW, Deng G, et al. (2008) Aberrant expression of SOX2 upregulates MUC5AC gastric foveolar mucin in mucinous cancers of the colorectum and related lesions. Int J Cancer 122: 1253-1260. (Pubitemid 351287224)
9. Rodriguez-Pinilla SM, Sarrio D, Moreno-Bueno G, Rodriguez-Gil Y, Martinez MA, et al. (2007) Sox2: a possible driver of the basal-like phenotype in sporadic breast cancer. Mod Pathol 20: 474-481. (Pubitemid 46482371)
10. Sanada Y, Yoshida K, Ohara M, Oeda M, Konishi K, et al. (2006) Histopathologic evaluation of stepwise progression of pancreatic carcinoma with immunohistochemical analysis of gastric epithelial transcription factor SOX2: comparison of expression patterns between invasive components and cancerous or nonneoplastic intraductal components. Pancreas 32: 164-170.
11. Li XL, Eishi Y, Bai YQ, Sakai H, Akiyama Y, et al. (2004) Expression of the SRY-related HMG box protein SOX2 in human gastric carcinoma. Int J Oncol 24: 257-263.
12. Ruan J, Wei B, Xu Z, Yang S, Zhou Y, et al. (2013) Predictive value of Sox2 expression in transurethral resection specimens in patients with T1 bladder cancer. Med Oncol 30: 445.
13. Cimpean AM, Encica S, Raica M, Ribatti D (2011) SOX2 gene expression in normal human thymus and thymoma. Clin Exp Med 11: 251-254.
14. Gallo M, Ho J, Coutinho FJ, Vanner R, Lee L, et al. (2013) A tumorigenic MLL-homeobox network in human glioblastoma stem cells. Cancer Res 73: 417-427.
15. Hindson BJ, Ness KD, Masquelier DA, Belgrader P, Heredia NJ, et al. (2011) High-throughput droplet digital PCR system for absolute quantitation of DNA copy number. Anal Chem 83: 8604-8610.
16. Pinheiro LB, Coleman VA, Hindson CM, Herrmann J, Hindson BJ, et al. (2012) Evaluation of a droplet digital polymerase chain reaction format for DNA copy number quantification. Anal Chem 84: 1003-1011.
17. Benlloch S, Paya A, Alenda C, Bessa X, Andreu M, et al. (2006) Detection of BRAF V600E mutation in colorectal cancer: comparison of automatic sequencing and real-time chemistry methodology. J Mol Diagn 8: 540-543. (Pubitemid 44774151)
18. Johnson BE, Mazor T, Hong C, Barnes M, Aihara K, et al. (2014) Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science 343: 189-193.
19. Weisenberger DJ, Siegmund KD, Campan M, Young J, Long TI, et al. (2006) CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet 38: 787-793. (Pubitemid 43980599)
20. Dahlin AM, Palmqvist R, Henriksson ML, Jacobsson M, Eklof V, et al. (2010) The role of the CpG island methylator phenotype in colorectal cancer prognosis depends on microsatellite instability screening status. Clin Cancer Res 16: 1845-1855.
21. Eklof V, Wikberg ML, Edin S, Dahlin AM, Jonsson BA, et al. (2013) The prognostic role of KRAS, BRAF, PIK3CA and PTEN in colorectal cancer. Br J Cancer 108: 2153-2163.
22. Cantwell-Dorris ER, O'Leary JJ, Sheils OM (2011) BRAFV600E: implications for carcinogenesis and molecular therapy. Mol Cancer Ther 10: 385-394.
23. Haugsten EM, Wiedlocha A, Olsnes S, Wesche J (2010) Roles of fibroblast growth factor receptors in carcinogenesis. Mol Cancer Res 8: 1439-1452.
24. Turner N, Grose R (2010) Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer 10: 116-129.
25. Liu K, Lin B, Zhao M, Yang X, Chen M, et al. (2013) The multiple roles for Sox2 in stem cell maintenance and tumorigenesis. Cell Signal 25: 1264-1271.
26. Ben-Porath I, Thomson MW, Carey VJ, Ge R, Bell GW, et al. (2008) An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet 40: 499-507. (Pubitemid 351601215)
27. Tang XB, Shen XH, Li L, Zhang YF, Chen GQ (2013) SOX2 overexpression correlates with poor prognosis in laryngeal squamous cell carcinoma. Auris Nasus Larynx 40: 481-486.
28. Pham DL, Scheble V, Bareiss P, Fischer A, Beschorner C, et al. (2013) SOX2 expression and prognostic significance in ovarian carcinoma. Int J Gynecol Pathol 32: 358-367.
29. Lou X, Han X, Jin C, Tian W, Yu W, et al. (2013) SOX2 targets fibronectin 1 to promote cell migration and invasion in ovarian cancer: new molecular leads for therapeutic intervention. OMICS 17: 510-518.
30. Xiang R, Liao D, Cheng T, Zhou H, Shi Q, et al. (2011) Downregulation of transcription factor SOX2 in cancer stem cells suppresses growth and metastasis of lung cancer. Br J Cancer 104: 1410-1417.
31. Girouard SD, Laga AC, Mihm MC, Scolyer RA, Thompson JF, et al. (2012) SOX2 contributes to melanoma cell invasion. Lab Invest 92: 362-370.
32. Peyssonnaux C, Eychene A (2001) The Raf/MEK/ERK pathway: new concepts of activation. Biol Cell 93: 53-62. (Pubitemid 33040860)
33. Baldus SE, Schaefer KL, Engers R, Hartleb D, Stoecklein NH, et al. (2010) Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases. Clin Cancer Res 16: 790-799.
34. Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, Zanon C, Moroni M, et al. (2007) Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res 67: 2643-2648. (Pubitemid 46548951)
35. Samowitz WS, Sweeney C, Herrick J, Albertsen H, Levin TR, et al. (2005) Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. Cancer Res 65: 6063-6069.
36. Ogino S, Nosho K, Kirkner GJ, Kawasaki T, Meyerhardt JA, et al. (2009) CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut 58: 90-96.
37. Phipps AI, Buchanan DD, Makar KW, Win AK, Baron JA, et al. (2013) KRAS-mutation status in relation to colorectal cancer survival: the joint impact of correlated tumour markers. Br J Cancer 108: 1757-1764.
38. Jang JH (2005) Reciprocal relationship in gene expression between FGFR1 and FGFR3: implication for tumorigenesis. Oncogene 24: 945-948.
39. Sato T, Oshima T, Yoshihara K, Yamamoto N, Yamada R, et al. (2009) Overexpression of the fibroblast growth factor receptor-1 gene correlates with liver metastasis in colorectal cancer. Oncol Rep 21: 211-216.
40. Yang F, Gao Y, Geng J, Qu D, Han Q, et al. (2013) Elevated expression of SOX2 and FGFR1 in correlation with poor prognosis in patients with small cell lung cancer. Int J Clin Exp Pathol 6: 2846-2854.